6,789 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Acquired by Commerce Bank

Commerce Bank purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 6,789 shares of the biopharmaceutical company's stock, valued at approximately $204,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Barclays PLC raised its holdings in TG Therapeutics by 83.9% in the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock valued at $8,117,000 after buying an additional 158,323 shares during the period. Synovus Financial Corp acquired a new stake in shares of TG Therapeutics during the third quarter valued at about $465,000. Franklin Resources Inc. raised its stake in shares of TG Therapeutics by 3.8% in the 3rd quarter. Franklin Resources Inc. now owns 128,985 shares of the biopharmaceutical company's stock valued at $2,945,000 after acquiring an additional 4,756 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of TG Therapeutics by 1,549.4% in the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock worth $18,061,000 after acquiring an additional 725,371 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of TG Therapeutics by 60.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company's stock worth $16,859,000 after purchasing an additional 270,286 shares during the period. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics Stock Up 2.6 %

Shares of NASDAQ TGTX traded up $1.03 during mid-day trading on Friday, hitting $41.33. The company had a trading volume of 1,464,365 shares, compared to its average volume of 3,086,120. The company has a market capitalization of $6.56 billion, a PE ratio of -413.26 and a beta of 2.14. The business's 50-day simple moving average is $37.18 and its 200 day simple moving average is $32.59. TG Therapeutics, Inc. has a 1-year low of $12.93 and a 1-year high of $43.32. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.07. The company had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. On average, analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analysts Set New Price Targets

TGTX has been the topic of a number of research reports. HC Wainwright restated a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.